Skip to main content
Top
Published in: BMC Medical Research Methodology 1/2018

Open Access 01-12-2018 | Research article

Joint modeling of multivariate longitudinal data and survival data in several observational studies of Huntington’s disease

Authors: Jeffrey D. Long, James A. Mills

Published in: BMC Medical Research Methodology | Issue 1/2018

Login to get access

Abstract

Background

Joint modeling is appropriate when one wants to predict the time to an event with covariates that are measured longitudinally and are related to the event. An underlying random effects structure links the survival and longitudinal submodels and allows for individual-specific predictions. Multiple time-varying and time-invariant covariates can be included to potentially increase prediction accuracy. The goal of this study was to estimate a multivariate joint model on several longitudinal observational studies of Huntington’s disease, examine external validity performance, and compute individual-specific predictions for characterizing disease progression. Emphasis was on the survival submodel for predicting the hazard of motor diagnosis.

Methods

Data from four observational studies was analyzed: Enroll-HD, PREDICT-HD, REGISTRY, and Track-HD. A Bayesian approach to estimation was adopted, and external validation was performed using a time-varying AUC measure. Individual-specific cumulative hazard predictions were computed based on a simulation approach. The cumulative hazard was used for computing predicted age of motor onset and also for a deviance residual indicating the discrepancy between observed diagnosis status and model-based status.

Results

The joint model trained in a single study had very good performance in discriminating among diagnosed and pre-diagnosed participants in the remaining test studies, with the 5-year mean AUC = .83 (range .77–.90), and the 10-year mean AUC = .86 (range .82–.92). Graphical analysis of the predicted age of motor diagnosis showed an expected strong relationship with the trinucleotide expansion that causes Huntington’s disease. Graphical analysis of the deviance-type residual revealed there were individuals who converted to a diagnosis despite having relatively low model-based risk, others who had not yet converted despite having relatively high risk, and the majority falling between the two extremes.

Conclusions

Joint modeling is an improvement over traditional survival modeling because it considers all the longitudinal observations of covariates that are predictive of an event. Predictions from joint models can have greater accuracy because they are tailored to account for individual variability. These predictions can provide relatively accurate characterizations of individual disease progression, which might be important in the timing of interventions, determining the qualification for appropriate clinical trials, and general genotypic analysis.
Literature
1.
go back to reference Therneau TM, Grambsch PM. Modeling survival data: extending the cox model. New York, NY: Springer; 2010. Therneau TM, Grambsch PM. Modeling survival data: extending the cox model. New York, NY: Springer; 2010.
2.
go back to reference Kalbfleisch JP, Prentice RL. The statistical analysis of failure time data. New York: Wiley-Interscience; 2002.CrossRef Kalbfleisch JP, Prentice RL. The statistical analysis of failure time data. New York: Wiley-Interscience; 2002.CrossRef
3.
go back to reference Elashoff RM, Li G, Li N. Joint modeling of longitudinal and time-to-event data. Boca Raton, FL: CRC Press; 2017. Elashoff RM, Li G, Li N. Joint modeling of longitudinal and time-to-event data. Boca Raton, FL: CRC Press; 2017.
4.
go back to reference Proust-Lima C, Sene M, Taylor JMG, Jacqmin-Gadda H. Joint latent class models for longitudinal and time-to-event data: a review. Stat Methods Med Res. 2014;23:74–90.CrossRef Proust-Lima C, Sene M, Taylor JMG, Jacqmin-Gadda H. Joint latent class models for longitudinal and time-to-event data: a review. Stat Methods Med Res. 2014;23:74–90.CrossRef
5.
go back to reference Rizopoulos D. Joint models for longitudinal and time-to-event data. Boca Raton, FL: CRC Press; 2012.CrossRef Rizopoulos D. Joint models for longitudinal and time-to-event data. Boca Raton, FL: CRC Press; 2012.CrossRef
6.
go back to reference Rizopoulos D, Taylor JM, Van Rosmalen J, Steyerberg EW, Takkenberg JJ. Personalized screening intervals for biomarkers using joint models for longitudinal and survival data. Biostatistics. 2016;17:149–64.PubMed Rizopoulos D, Taylor JM, Van Rosmalen J, Steyerberg EW, Takkenberg JJ. Personalized screening intervals for biomarkers using joint models for longitudinal and survival data. Biostatistics. 2016;17:149–64.PubMed
7.
go back to reference Schork NJ. Personalized medicine: time for one-person trials. Nature. 2015;520:609–11.CrossRef Schork NJ. Personalized medicine: time for one-person trials. Nature. 2015;520:609–11.CrossRef
8.
go back to reference Huntington Study Group PHAROS Investigators. Clinical-genetic associations in the prospective Huntington at risk observational study (PHAROS). JAMA Neurology. 2016;73:102–10.CrossRef Huntington Study Group PHAROS Investigators. Clinical-genetic associations in the prospective Huntington at risk observational study (PHAROS). JAMA Neurology. 2016;73:102–10.CrossRef
9.
go back to reference Paulsen JS, Hayden M, Stout JC, Langbehn DR, Aylward E, Ross CA, et al. Preparing for preventive clinical trials the predict-HD study. Arch Neurol. 2006;63:883–90.CrossRef Paulsen JS, Hayden M, Stout JC, Langbehn DR, Aylward E, Ross CA, et al. Preparing for preventive clinical trials the predict-HD study. Arch Neurol. 2006;63:883–90.CrossRef
10.
go back to reference Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, et al. Detection of Huntington’s disease decades before diagnosis the PREDICT-HD study. J Neurol Neurosurg Psychiatry. 2008;79:874–80.CrossRef Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, et al. Detection of Huntington’s disease decades before diagnosis the PREDICT-HD study. J Neurol Neurosurg Psychiatry. 2008;79:874–80.CrossRef
11.
go back to reference Paulsen JS, Wang C, Duff K, Barker R, Nance M, Beglinger L, et al. Challenges assessing clinical endpoints in early Huntington disease. Mov Disord. 2010;15:2595–603.CrossRef Paulsen JS, Wang C, Duff K, Barker R, Nance M, Beglinger L, et al. Challenges assessing clinical endpoints in early Huntington disease. Mov Disord. 2010;15:2595–603.CrossRef
12.
go back to reference Paulsen JS, Long JD, Johnson HJ, Aylward EH, Ross CA, Williams JK, et al. Clinical and biomarker changes in premanifest Huntington disease show trial feasibility a decade of the PREDICT-HD study. Front Aging Neurosci. 2014;6:1–11.CrossRef Paulsen JS, Long JD, Johnson HJ, Aylward EH, Ross CA, Williams JK, et al. Clinical and biomarker changes in premanifest Huntington disease show trial feasibility a decade of the PREDICT-HD study. Front Aging Neurosci. 2014;6:1–11.CrossRef
13.
go back to reference Paulsen J, Long J, Ross C, Harrington D, Erwin C, Williams J, et al. Prediction of manifest Huntington’s disease with clinical and imaging measures: a prospective observational study. Lancet Neurol. 2014;13:1193–201.CrossRef Paulsen J, Long J, Ross C, Harrington D, Erwin C, Williams J, et al. Prediction of manifest Huntington’s disease with clinical and imaging measures: a prospective observational study. Lancet Neurol. 2014;13:1193–201.CrossRef
14.
go back to reference Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study cross-sectional analysis of baseline data. Lancet Neurol. 2009;8:791–801.CrossRef Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study cross-sectional analysis of baseline data. Lancet Neurol. 2009;8:791–801.CrossRef
15.
go back to reference Tabrizi S, Scahill R, Durr A, Roos R, Leavitt B, Jones R, et al. Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study the 12-month longitudinal analysis. Lancet Neurol. 2011;10:31–42.CrossRef Tabrizi S, Scahill R, Durr A, Roos R, Leavitt B, Jones R, et al. Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study the 12-month longitudinal analysis. Lancet Neurol. 2011;10:31–42.CrossRef
16.
go back to reference Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study analysis of 36-month observational data. Lancet Neurol. 2013;12:637–49.CrossRef Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study analysis of 36-month observational data. Lancet Neurol. 2013;12:637–49.CrossRef
17.
go back to reference Landwehrmeyer BG, Fitter-Attas C, Giuliano J, et al. Data analytics from enroll-HD, a global clinical research platform for Huntington’s disease. Movement Disorder Clinical Practice. 2016;4:212–24.CrossRef Landwehrmeyer BG, Fitter-Attas C, Giuliano J, et al. Data analytics from enroll-HD, a global clinical research platform for Huntington’s disease. Movement Disorder Clinical Practice. 2016;4:212–24.CrossRef
18.
go back to reference Handley O, Landwehrmeyer B. REGISTRY steering committee and the EHDN REGISTRY investigators. European huntington’s disease network registry current status. Journal of neurology, neurosurgery, and. Psychiatry. 2012;83:A47. Handley O, Landwehrmeyer B. REGISTRY steering committee and the EHDN REGISTRY investigators. European huntington’s disease network registry current status. Journal of neurology, neurosurgery, and. Psychiatry. 2012;83:A47.
19.
go back to reference Orth M, Handley OJ, Schwenke C, Landwehrmeyer B. Observing Huntington’s disease the European Huntington’s disease network’s REGISTRY. J Neurol Neurosurg Psychiatry. 2010;82:1409–12.CrossRef Orth M, Handley OJ, Schwenke C, Landwehrmeyer B. Observing Huntington’s disease the European Huntington’s disease network’s REGISTRY. J Neurol Neurosurg Psychiatry. 2010;82:1409–12.CrossRef
20.
go back to reference Huntington Study Group. Unified Huntington’s disease rating scale reliability and-consistency. Mov Disord. 1996;11:136–42.CrossRef Huntington Study Group. Unified Huntington’s disease rating scale reliability and-consistency. Mov Disord. 1996;11:136–42.CrossRef
21.
go back to reference Long JD, Langbehn DR, Tabrizi SJ, Landwehrmeyer BG, Paulsen JS, Warner J, et al. Validation of a prognostic index for Huntington’s disease. Mov Disord. 2017;32:256–63.CrossRef Long JD, Langbehn DR, Tabrizi SJ, Landwehrmeyer BG, Paulsen JS, Warner J, et al. Validation of a prognostic index for Huntington’s disease. Mov Disord. 2017;32:256–63.CrossRef
22.
go back to reference Long JD, Paulsen JS. Multivariate prediction of motor diagnosis in Huntington disease: 12 years of PREDICT-HD. Mov Disord. 2015;12:1664–72.CrossRef Long JD, Paulsen JS. Multivariate prediction of motor diagnosis in Huntington disease: 12 years of PREDICT-HD. Mov Disord. 2015;12:1664–72.CrossRef
23.
go back to reference Zhang Y, Long JD, Mills JA, Warner JH, Lu W, Paulsen JS. Indexing disease progression at study entry with individuals at-risk for Huntington disease. American journal of medical genetics part B neuropsychiatric. Genetics. 2011;156:751–63. Zhang Y, Long JD, Mills JA, Warner JH, Lu W, Paulsen JS. Indexing disease progression at study entry with individuals at-risk for Huntington disease. American journal of medical genetics part B neuropsychiatric. Genetics. 2011;156:751–63.
24.
25.
go back to reference Long JD, Mills JA, Leavitt BR, Durr A, Roos RA, Stout JC, et al. Survival endpoints for Huntington’s disease trials prior to a motor diagnosis. JAMA Neurology. 2017;74:1–9.CrossRef Long JD, Mills JA, Leavitt BR, Durr A, Roos RA, Stout JC, et al. Survival endpoints for Huntington’s disease trials prior to a motor diagnosis. JAMA Neurology. 2017;74:1–9.CrossRef
26.
go back to reference Long JD, Paulsen JS, Marder K, Zhang Y, Kim J, Mills JA. Tracking motor impairments in the progression of Huntington’s disease. Mov Disord. 2014;29:311–9.CrossRef Long JD, Paulsen JS, Marder K, Zhang Y, Kim J, Mills JA. Tracking motor impairments in the progression of Huntington’s disease. Mov Disord. 2014;29:311–9.CrossRef
27.
go back to reference Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, et al. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology. 2012;78:690–5.CrossRef Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, et al. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology. 2012;78:690–5.CrossRef
28.
go back to reference Klein JP, Moeschberger ML. Survival analysis techniques for censored and truncated data. 2nd ed. New York. NY: Springer; 2003. Klein JP, Moeschberger ML. Survival analysis techniques for censored and truncated data. 2nd ed. New York. NY: Springer; 2003.
30.
go back to reference Rizopoulos D. The R package JMbayes for fitting joint models for longitudinal and time-to-event data using mcmc. J Stat Softw. 2016;72:1–45.CrossRef Rizopoulos D. The R package JMbayes for fitting joint models for longitudinal and time-to-event data using mcmc. J Stat Softw. 2016;72:1–45.CrossRef
31.
go back to reference Crowther MJ, Andersson TML, Lambert PC, Abrams KR, Humphreys K. Joint modelling of longitudinal and survival data: incorporating delayed entry and an assessment of model misspecification. Stat Med. 2016;35:1193–209.CrossRef Crowther MJ, Andersson TML, Lambert PC, Abrams KR, Humphreys K. Joint modelling of longitudinal and survival data: incorporating delayed entry and an assessment of model misspecification. Stat Med. 2016;35:1193–209.CrossRef
32.
go back to reference Rizopoulos D, Ghosh P. A Bayesian semiparametric multivariate joint model for multiple longitudina outcomes and a time-to-event. Statistics in Medicine. 2011;30:1366–80.CrossRef Rizopoulos D, Ghosh P. A Bayesian semiparametric multivariate joint model for multiple longitudina outcomes and a time-to-event. Statistics in Medicine. 2011;30:1366–80.CrossRef
33.
go back to reference Therneau TM, Grambsch PM, Fleming TR. Martingale-based residuals for survival models. Biometrika. 1990;77:147–60.CrossRef Therneau TM, Grambsch PM, Fleming TR. Martingale-based residuals for survival models. Biometrika. 1990;77:147–60.CrossRef
34.
go back to reference Royston P, Altman DG. External validation of a cox prognostic model principles and methods. BMC Med Res Methodol. 2013;13:33–48.CrossRef Royston P, Altman DG. External validation of a cox prognostic model principles and methods. BMC Med Res Methodol. 2013;13:33–48.CrossRef
35.
go back to reference Antolini L, Boracchi P. Biganzoli E. A time-dependent discrimination index for survival data. Stat Med. 2005;24:3927–44.CrossRef Antolini L, Boracchi P. Biganzoli E. A time-dependent discrimination index for survival data. Stat Med. 2005;24:3927–44.CrossRef
36.
go back to reference Harrell FE, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. J Am Med Assoc. 1982;247:2543–6.CrossRef Harrell FE, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. J Am Med Assoc. 1982;247:2543–6.CrossRef
37.
go back to reference Pencina MJ, D’Agostino RB, Song L. Quantifying discrimination of Framingham risk functions with different survival C statistics. Stat Med. 2012;31:1543–53.CrossRef Pencina MJ, D’Agostino RB, Song L. Quantifying discrimination of Framingham risk functions with different survival C statistics. Stat Med. 2012;31:1543–53.CrossRef
38.
go back to reference Long JD, Lee JM, Aylward EH, Gillis T, Mysore JS, Abu EK, et al. Genetic modification of Huntington disease acts early in the prediagnosis phase. Am J Hum Genet. 2018;103:349–57.CrossRef Long JD, Lee JM, Aylward EH, Gillis T, Mysore JS, Abu EK, et al. Genetic modification of Huntington disease acts early in the prediagnosis phase. Am J Hum Genet. 2018;103:349–57.CrossRef
39.
go back to reference Lee S, Abecasis GR, Boehnke M, Lin X. Rare-variant association analysis: study design and statistical tests. Am J Hum Genet. 2014;95:5–23.CrossRef Lee S, Abecasis GR, Boehnke M, Lin X. Rare-variant association analysis: study design and statistical tests. Am J Hum Genet. 2014;95:5–23.CrossRef
40.
go back to reference Collins GS, de GJA, Dutton S, Omar O, Shanyinde M, Tajar A, et al. External validation of multivariable prediction models: a systematic review of methodological conduct and reporting. BMC Med Res Methodol. 2014;14:40–51.CrossRef Collins GS, de GJA, Dutton S, Omar O, Shanyinde M, Tajar A, et al. External validation of multivariable prediction models: a systematic review of methodological conduct and reporting. BMC Med Res Methodol. 2014;14:40–51.CrossRef
41.
go back to reference Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21:128–38.CrossRef Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21:128–38.CrossRef
42.
go back to reference Gerds TA, Cai T, Schumacher M. The performance of risk prediction models. Biom J. 2008;4:457–79.CrossRef Gerds TA, Cai T, Schumacher M. The performance of risk prediction models. Biom J. 2008;4:457–79.CrossRef
43.
go back to reference Henderson T, Diggle P, Dobson A. Identification and efficacy of longitudinal markers for survival. Biostatistics. 2002;3:33–50.CrossRef Henderson T, Diggle P, Dobson A. Identification and efficacy of longitudinal markers for survival. Biostatistics. 2002;3:33–50.CrossRef
44.
go back to reference Pepe M, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic. or screening marker American Journal of Epidemiology. 2004;159:882–90.CrossRef Pepe M, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic. or screening marker American Journal of Epidemiology. 2004;159:882–90.CrossRef
45.
go back to reference Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157–72.CrossRef Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157–72.CrossRef
47.
go back to reference Spiegelhalter DJ, Best NG, Carlin BP, Van Der LA. Bayesian measures of model complexity and fit (with discussion). 2002;64:583–639. Spiegelhalter DJ, Best NG, Carlin BP, Van Der LA. Bayesian measures of model complexity and fit (with discussion). 2002;64:583–639.
48.
go back to reference Geisser S. Predictive inference: an introduction. London: Chapman; Hall. 1993.CrossRef Geisser S. Predictive inference: an introduction. London: Chapman; Hall. 1993.CrossRef
49.
go back to reference Ibrahim JG, Chen MH, Sinha D. Bayesian survival analysis. New York: Springer science+business Media; 2001.CrossRef Ibrahim JG, Chen MH, Sinha D. Bayesian survival analysis. New York: Springer science+business Media; 2001.CrossRef
50.
go back to reference Zhang D, Chen MH, Ibrahim JG, Boye ME, Shen W. Bayesian model assessment in joint modeling of longitudinal and survival data with applications to. cancer clinical trials. 2017;26:121–33. Zhang D, Chen MH, Ibrahim JG, Boye ME, Shen W. Bayesian model assessment in joint modeling of longitudinal and survival data with applications to. cancer clinical trials. 2017;26:121–33.
51.
go back to reference Schobel S, Palermo G, Auinger P, Long J, Ma S, Khwaja O, et al. Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. Neurology. 2017;89:2495–502.CrossRef Schobel S, Palermo G, Auinger P, Long J, Ma S, Khwaja O, et al. Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. Neurology. 2017;89:2495–502.CrossRef
52.
go back to reference Gusella JF, MacDonald ME. M. LJ. Genetic modifiers of Huntington’s disease. Mov Disord. 2014;29:1359–65.CrossRef Gusella JF, MacDonald ME. M. LJ. Genetic modifiers of Huntington’s disease. Mov Disord. 2014;29:1359–65.CrossRef
53.
go back to reference Guey L, Kravic J, Melander O, Burtt N, Laramie J, Lyssenko V, et al. Power in the phenotypic extremes: a simulation study of power in discovery and replication of rare variants. Genet Epidemiol. 2011;35:236–46.PubMed Guey L, Kravic J, Melander O, Burtt N, Laramie J, Lyssenko V, et al. Power in the phenotypic extremes: a simulation study of power in discovery and replication of rare variants. Genet Epidemiol. 2011;35:236–46.PubMed
54.
go back to reference Barnett IJ, Lee S, Lin X. Detecting rare variant effects using extreme phenotype sampling in sequencing association studies. Genet Epidemiol. 2013;37:142–51.CrossRef Barnett IJ, Lee S, Lin X. Detecting rare variant effects using extreme phenotype sampling in sequencing association studies. Genet Epidemiol. 2013;37:142–51.CrossRef
55.
go back to reference D’Agostino R, Vasan R, Pencina M, Wolf P, Cobain M, Massaro J, et al. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. 2008;117. D’Agostino R, Vasan R, Pencina M, Wolf P, Cobain M, Massaro J, et al. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. 2008;117.
56.
go back to reference Henderson R, Keiding N. Individual survival time prediction using statistical models. J Med Ethics. 2005;31:703–6.CrossRef Henderson R, Keiding N. Individual survival time prediction using statistical models. J Med Ethics. 2005;31:703–6.CrossRef
57.
go back to reference Li K, Furr-Stimming E, Paulsen JS, Luo S. Dynamic prediction of motor diagnosis in Huntington’s disease using a joint modeling approach. Journal of Huntington’s Disease. 2017;6:127–37.CrossRef Li K, Furr-Stimming E, Paulsen JS, Luo S. Dynamic prediction of motor diagnosis in Huntington’s disease using a joint modeling approach. Journal of Huntington’s Disease. 2017;6:127–37.CrossRef
58.
go back to reference Pencina MJ, Larson MG, D’Agostino RB. Choice of time scale and its effect on significance of predictors in longitudinal studies. Stat Med. 2007;26:1343–59.CrossRef Pencina MJ, Larson MG, D’Agostino RB. Choice of time scale and its effect on significance of predictors in longitudinal studies. Stat Med. 2007;26:1343–59.CrossRef
59.
go back to reference Cologne J, Hsu WL, Abbott RD, Ohishi W, Grant EJ, Fujiwara S, et al. Proportional hazards regression in epidemiologic follow-up studies: an intuitive consideration of primary time scale. Epidemiology. 2012;23:565–73.CrossRef Cologne J, Hsu WL, Abbott RD, Ohishi W, Grant EJ, Fujiwara S, et al. Proportional hazards regression in epidemiologic follow-up studies: an intuitive consideration of primary time scale. Epidemiology. 2012;23:565–73.CrossRef
60.
go back to reference Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol. 1997;145:72–80.CrossRef Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol. 1997;145:72–80.CrossRef
61.
go back to reference Thiebaut A, Benichou J. Choice of time-scale in cox’s model analysis of epidemiologic cohort data: a simulation study. Stat Med. 2004;23:3803–20.CrossRef Thiebaut A, Benichou J. Choice of time-scale in cox’s model analysis of epidemiologic cohort data: a simulation study. Stat Med. 2004;23:3803–20.CrossRef
Metadata
Title
Joint modeling of multivariate longitudinal data and survival data in several observational studies of Huntington’s disease
Authors
Jeffrey D. Long
James A. Mills
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Medical Research Methodology / Issue 1/2018
Electronic ISSN: 1471-2288
DOI
https://doi.org/10.1186/s12874-018-0592-9

Other articles of this Issue 1/2018

BMC Medical Research Methodology 1/2018 Go to the issue